A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers

By Gelmon K.   Hirte H.   Fisher B.   Walsh W.   Ptaszynski M.   Hamilton M.   Onetto N.   Eisenhauer E.  

Investigational New Drugs, Vol. 22, Iss. 3, 2004-08 ,pp. : 263-275

Springer Publishing Company

Access to resources Recommend Favorite

Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors

By Hubbard Joleen   Erlichman Charles   Toft David   Qin Rui   Stensgard Bridget   Felten Sara   Ten Eyck Cynthia   Batzel Gretchen   Ivy S.   Haluska Paul  

Investigational New Drugs, Vol. 29, Iss. 3, 2011-06 ,pp. : 473-480

Springer Publishing Company

Access to resources Recommend Favorite

Weekly Gemcitabine plus Fluorouracil-Folinic Acid Given Weekly for Two Days in Patients with Advanced Pancreatic Cancer: A Phase II Study

By Aristides Polyzos  

Clinical Drug Investigation, Vol. 24, Iss. 11, 2004-01 ,pp. : 661-670

Adis International

Access to resources Recommend Favorite

Phase I study of Vinflunine administered as a 10-minute infusion on days 1 and 8 every 3 weeks

By Johnson Peter   Geldart Thomas   Fumoleau Pierre   Pinel Marie-Claire   Nguyen Laurent   Judson Ian  

Investigational New Drugs, Vol. 24, Iss. 3, 2006-05 ,pp. : 223-231

Springer Publishing Company

Access to resources Recommend Favorite

Gemcitabine plus cisplatin for NSCLC

By  

Inpharma, Vol. 1, Iss. 1222, 2000-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite